Entera Bio Ltd. ENTX

ENTX Company Overview

Entera Bio Ltd. is a clinical-stage biotechnology company focused on the oral delivery of biologic therapies and large molecules that are traditionally administered by injection. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on developing oral formulations for peptides, proteins, and other biologics using its proprietary delivery platform technology. Entera Bio’s primary revenue and value drivers are tied to the advancement, licensing potential, and commercialization prospects of its clinical pipeline, particularly oral formulations targeting bone health and metabolic diseases.

The company’s core technology platform, known as N-Tab™, is designed to enable the oral absorption of biologic compounds by improving gastrointestinal delivery and bioavailability. Entera Bio has concentrated development efforts on oral peptide therapeutics, including programs related to parathyroid hormone and GLP-1 receptor agonists. Founded in Israel and later listed on the Nasdaq Capital Market under the ticker ENTX, the company evolved from a platform-focused drug delivery developer into a clinical-stage therapeutics company with strategic collaborations in endocrinology and metabolic disease markets.